PRESeNT: Exposures to Perinatal Adverse Experiences: Multimodal Omics Signature of Stress Vulnerability and Resilience and Preventive Strategies

Sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli (Other)
Overall Status
Recruiting
CT.gov ID
NCT05951738
Collaborator
(none)
240
4
3
40.6
60
1.5

Study Details

Study Description

Brief Summary

The study aims at identifying:
  1. specific biological and molecular alterations associated with development of depression in pregnancy or risk of it.

  2. specific biological and molecular alterations due to exposure to maternal depression in utero that are still present in the offspring, that could possibly mediate the development of negative outcomes, and which are the possible clinical moderators of the associated risk;

  3. whether antidepressant therapies prescribed by personal physician and the use of digital tools can have a preventive effect in the transmission of the risk from mothers to babies and in the development of depressive symptoms in high-risk pregnant women;

In order to achieve these, 80 pregnant women with depression, 80 at high-risk and 80 controls will be recruited and clinically monitored over pregnancy and postpartum along with their babies, specifically at these timepoints: 25th and 32nd weeks of gestation, 1 week postpartum, 4 weeks postpartum, 8 weeks postpartum, 12 months postpartum.

Women, based on their clinician choice, will receive antidepressants and will be provided with a smartphone app to monitor them, using a combination of personalised, daily self-reported assessments and sensors for passive data collection to cover mental and physical health.

Blood and saliva samples from pregnant women will be collected at the 25th and 32nd week of gestation to perform biological analyses.

Saliva samples from babies will be collected at 8 weeks and 12 months postpartum to perform biological analyses.

Clinical and psychological data will be collected from women at all timepoints.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Blood and saliva collection
  • Behavioral: Psychometric scales
  • Other: Smartphone app
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Exposures to PRenatal and Postnatal Adverse Stressful Experiences: Multimodal Omics Signatures Underlying Stress Vulnerability and Resilience and as Novel Targets for Preventive Strategies.
Actual Study Start Date :
Feb 11, 2022
Anticipated Primary Completion Date :
Jul 1, 2025
Anticipated Study Completion Date :
Jul 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Depressed

Procedure: Blood and saliva collection
Blood and saliva samples from pregnant women; saliva samples from babies.

Behavioral: Psychometric scales
A battery of psychometric scales and questionnaires.

Other: Smartphone app
A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.

Other: At high risk

Procedure: Blood and saliva collection
Blood and saliva samples from pregnant women; saliva samples from babies.

Behavioral: Psychometric scales
A battery of psychometric scales and questionnaires.

Other: Smartphone app
A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.

Other: Control

Procedure: Blood and saliva collection
Blood and saliva samples from pregnant women; saliva samples from babies.

Behavioral: Psychometric scales
A battery of psychometric scales and questionnaires.

Other: Smartphone app
A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.

Outcome Measures

Primary Outcome Measures

  1. Differentially expressed genes and biological pathways modulation [25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies.]

Secondary Outcome Measures

  1. Rate and profile of DNA methylation [25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies.]

  2. Cortisol levels [25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies.]

  3. Immune-related factors levels [25th and 32nd weeks of gestation for pregnant women; 8 weeks and 12 months postpartum for babies.]

  4. Smartphone app utility [From 25th of gestation to 12 months postpartum]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Pregnant women of a singleton pregnancy

  • Age ≥ 18 years

Exclusion Criteria:
  • Uterine anomalies and obstetric complications

  • Comorbidity with severe or chronic diseases

  • Substance abuse

  • Language barrier

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Centro San Giovanni di Dio Fatebenefratelli Brescia Italy 25125
2 Centro Psiche Donna - Ospedale Macedonio Melloni - ASST Fatebenefratelli Sacco Milano Italy
3 Ospedale San Raffaele Milano Italy
4 ASST Bergamo ovest Treviglio Italy

Sponsors and Collaborators

  • IRCCS Centro San Giovanni di Dio Fatebenefratelli

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Annamaria Cattaneo, Head of the Biological Psichiatry unit, IRCCS Centro San Giovanni di Dio Fatebenefratelli
ClinicalTrials.gov Identifier:
NCT05951738
Other Study ID Numbers:
  • PRESeNT
  • 1749118
First Posted:
Jul 19, 2023
Last Update Posted:
Jul 19, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2023